Trials / Completed
CompletedNCT03959332
Study to Assess the Pharmacokinetics, Safety and Tolerability of Baloxavir Marboxil in Healthy Chinese Participants
A Phase I, Single-Centre, Open-Label, Parallel, Two Dose Level Study to Investigate the Pharmacokinetics, Safety, and Tolerability Following a Single Dose of Baloxavir Marboxil in Healthy Chinese Volunteers
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 20 Years – 59 Years
- Healthy volunteers
- Accepted
Summary
This study will evaluate the pharmacokinetics, safety and tolerability of a single oral dose of baloxavir marboxil (40 mg or 80 mg) in healthy Chinese participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Baloxavir Marboxil | Participants will receive either 40 mg or 80 mg of baloxavir marboxil on Day 1 as a single oral dose. |
Timeline
- Start date
- 2019-06-19
- Primary completion
- 2019-07-11
- Completion
- 2019-07-11
- First posted
- 2019-05-22
- Last updated
- 2020-08-11
- Results posted
- 2020-06-22
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03959332. Inclusion in this directory is not an endorsement.